ARNA Arena Pharmaceuticals, Inc.

1.40
+0.03  (2.19%)
Previous Close 1.37
Open 1.37
Price To book 97.86
Market Cap 340.64M
Shares 243,313,000
Volume 1,392,100
Short Ratio 5.38
Av. Daily Volume 1,626,430

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536795
  2. 8-K - Current report 17514760
  3. 8-K - Current report 17505727
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17505639
  5. 8-K - Current report 17505534

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2017 with data due by the end of 2017.
APD371
Pain associated with Crohn’s disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 2 data due by the end of 2017.
APD334
Ulcerative colitis
Phase 2 data due 3Q 2017.
Ralinepag
Pulmonary Arterial Hypertension

Latest News

  1. Why Arena Pharmaceuticals Stock Sank in 2016
  2. Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
  3. Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
  4. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  5. Arena Pharmaceuticals Dumps Belviq Weight Loss Drug
  6. Genocea Stock Up on Positive Genital Herpes Infections Data
  7. Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
  8. Arena, Eisai Modify Marketing & Supply Agreement for Belviq
  9. Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
  10. Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
  11. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017
  12. Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin
  13. ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
  14. Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally
  15. Clovis Declares Pricing of Upsized Offering of Common Stock
  16. Allergan Natrelle Inspira Breast Implants Approved in the U.S.
  17. Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : December 27, 2016
  18. Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : December 26, 2016
  19. Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil
  20. ETFs with exposure to Arena Pharmaceuticals, Inc. : December 19, 2016

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536795
  2. 8-K - Current report 17514760
  3. 8-K - Current report 17505727
  4. 424B5 - Prospectus [Rule 424(b)(5)] 17505639
  5. 8-K - Current report 17505534
  6. S-8 - Securities to be offered to employees in employee benefit plans 161984422
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984244
  8. 8-K - Current report 161978283
  9. 8-K - Current report 161914599
  10. UPLOAD [Cover] - SEC-generated letter